122 related articles for article (PubMed ID: 8898421)
1. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin.
Gilbert JA; Ahlquist DA; Mahoney DW; Zinsmeister AR; Rubin J; Ellefson RD
Scand J Gastroenterol; 1996 Oct; 31(10):1001-5. PubMed ID: 8898421
[TBL] [Abstract][Full Text] [Related]
2. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method.
Johne B; Kronborg O; Tøn HI; Kristinsson J; Fuglerud P
Scand J Gastroenterol; 2001 Mar; 36(3):291-6. PubMed ID: 11305517
[TBL] [Abstract][Full Text] [Related]
3. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
[TBL] [Abstract][Full Text] [Related]
4. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy.
Limburg PJ; Ahlquist DA; Sandborn WJ; Mahoney DW; Devens ME; Harrington JJ; Zinsmeister AR
Am J Gastroenterol; 2000 Oct; 95(10):2831-7. PubMed ID: 11051356
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
6. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics.
Kristinsson J; Armbruster CH; Ugstad M; Kriwanek S; Nygaard K; Tøn H; Fuglerud P
Scand J Gastroenterol; 2001 Feb; 36(2):202-7. PubMed ID: 11252414
[TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin concentration in patients with colorectal carcinoma.
Kristinsson J; Røseth A; Fagerhol MK; Aadland E; Schjønsby H; Børmer OP; Raknerud N; Nygaard K
Dis Colon Rectum; 1998 Mar; 41(3):316-21. PubMed ID: 9514426
[TBL] [Abstract][Full Text] [Related]
8. Faecal calprotectin levels in a high risk population for colorectal neoplasia.
Kronborg O; Ugstad M; Fuglerud P; Johne B; Hardcastle J; Scholefield JH; Vellacott K; Moshakis V; Reynolds JR
Gut; 2000 Jun; 46(6):795-800. PubMed ID: 10807890
[TBL] [Abstract][Full Text] [Related]
9. Improved assay for fecal calprotectin.
Tøn H; Brandsnes ; Dale S; Holtlund J; Skuibina E; Schjønsby H; Johne B
Clin Chim Acta; 2000 Feb; 292(1-2):41-54. PubMed ID: 10686275
[TBL] [Abstract][Full Text] [Related]
10. Stool markers for colorectal cancer screening: future considerations.
Ahlquist DA; Gilbert JA
Dig Dis; 1996; 14(3):132-44. PubMed ID: 8861521
[TBL] [Abstract][Full Text] [Related]
11. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.
Kristinsson J; Nygaard K; Aadland E; Barstad S; Sauar J; Hofstad B; Stray N; Stallemo A; Haug B; Ugstad M; Tøn H; Fuglerud P
Digestion; 2001; 64(2):104-10. PubMed ID: 11684824
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of fecal calprotectin as a screening biomarker for gastrointestinal malignancies.
Khoshbaten M; Pishahang P; Nouri M; Lashkari A; Alizadeh M; Rostami-Nejad M
Asian Pac J Cancer Prev; 2014; 15(4):1667-70. PubMed ID: 24641386
[TBL] [Abstract][Full Text] [Related]
13. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm.
Husebye E; Tøn H; Johne B
Am J Gastroenterol; 2001 Sep; 96(9):2683-7. PubMed ID: 11569695
[TBL] [Abstract][Full Text] [Related]
14. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
[TBL] [Abstract][Full Text] [Related]
15. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
Inflamm Bowel Dis; 2014 Feb; 20(2):307-14. PubMed ID: 24374878
[TBL] [Abstract][Full Text] [Related]
16. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?
Røseth AG; Kristinsson J; Fagerhol MK; Schjønsby H; Aadland E; Nygaard K; Roald B
Scand J Gastroenterol; 1993 Dec; 28(12):1073-6. PubMed ID: 8303210
[TBL] [Abstract][Full Text] [Related]
17. Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.
Lehmann FS; Trapani F; Fueglistaler I; Terracciano LM; von Flüe M; Cathomas G; Zettl A; Benkert P; Oertli D; Beglinger C
World J Gastroenterol; 2014 May; 20(17):4994-9. PubMed ID: 24803811
[TBL] [Abstract][Full Text] [Related]
18. [Fecal calprotectin in differential diagnosis of irritable bowel syndrome].
Li XG; Lu YM; Gu F; Yang XL
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):310-3. PubMed ID: 16778979
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum.
Rutka M; Bor R; Bálint A; Fábián A; Milassin Á; Nagy F; Szepes Z; Szűcs M; Tiszlavicz L; Farkas K; Molnár T
Mediators Inflamm; 2016; 2016():2492081. PubMed ID: 27413251
[TBL] [Abstract][Full Text] [Related]
20. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
